Imaging of dopamine transporters: Biomarker for progression in Parkinson's disease

被引：0
|
作者：
Innis, RB [1 ]
Seibyl, J
Marek, K
机构：
[1] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA
[3] Yale Univ, Sch Med, Dept Neurol & Diagnost Radiol, New Haven, CT 06510 USA
来源：
CNS DRUG REVIEWS | 2000年 / 6卷
关键词：
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [31] Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease - Reply
    Marek, K
    Seibyl, J
    McDermott, M
    Fahn, S
    Lang, A
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (03): : 312 - 313
  • [32] [123I]β-CIT SPEICT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy
    Berding, G
    Brücke, T
    Odin, P
    Brooks, DJ
    Kolbe, H
    Gielow, P
    Harke, H
    Knoop, BO
    Dengler, R
    Knapp, WH
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2003, 42 (01): : 31 - 38
  • [33] Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease
    Booij, J
    Habraken, JBA
    Bergmans, P
    Tissingh, G
    Winogrodzka, A
    Wolters, EC
    Janssen, AGM
    Stoof, JC
    van Royen, EA
    JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (11) : 1879 - 1884
  • [34] Imaging of dopamine transporters in the human brain in healthy and Parkinson's disease with [99mTc]TRODAT/SPECT.
    Tzen, KY
    Kao, PF
    Yen, TC
    JOURNAL OF NUCLEAR MEDICINE, 1999, 40 (05) : 27P - 27P
  • [35] 99mTc-TRODAT-1 SPECT imaging of dopamine transporters in healthy subjects and Parkinson's disease patients
    Weng, YH
    Yen, TC
    Kao, PF
    Tsai, CH
    Chen, RS
    Tzen, KY
    Lu, CS
    NEUROLOGY, 2000, 54 (07) : A330 - A330
  • [36] Substantia nigra area evaluated by neuromelanin-sensitive MRI as an imaging biomarker of disease progression in Parkinson's disease
    Fabbri, M.
    Reimao, S.
    Carbalho, M.
    Nunes, R.
    Abreu, D.
    Guedes, L.
    Bouca, R.
    Lobo, P.
    Godinho, C.
    Coelho, M.
    Goncalves, N.
    Rosa, M.
    Antonini, A.
    Ferreira, J.
    MOVEMENT DISORDERS, 2017, 32
  • [37] The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease
    Ahlskog, JE
    Uitti, RJ
    O'Connor, MK
    Maraganore, DM
    Matsumoto, JY
    Stark, KF
    Turk, MF
    Burnett, OL
    MOVEMENT DISORDERS, 1999, 14 (06) : 940 - 946
  • [38] Substantia nigra area evaluated by neuromelanin-sensitive MRI as an imaging biomarker of disease progression in Parkinson's disease
    Fabbri, M.
    Reimao, S.
    Carvalho, M.
    Nunes, R.
    Guedes, L.
    Bouca, R.
    Lobo, A. P. S. P.
    Godinho, C.
    Coelho, M.
    Abreu, D.
    Goncalves, N.
    Rosa, M.
    Antonini, A.
    Ferreira, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 485 - 485
  • [39] Effects of the capacity of dopamine sequestration on the rate of progression in Parkinson's disease
    Qasem, A
    Schulzer, M
    Sossi, V
    Ruth, TJ
    Calne, DB
    Stoessl, AJ
    Lee, CS
    NEUROLOGY, 2005, 64 (06) : A274 - A275
  • [40] Do dopamine agonists or levodopa modify Parkinson's disease progression?
    Marek, K
    Jennings, D
    Seibyl, J
    EUROPEAN JOURNAL OF NEUROLOGY, 2002, 9 : 15 - 22
12345